ScoreWhy is Glenmark Pharmaceuticals Ltd. ?
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.13 times
2
Flat results in Jun 26
- PBT LESS OI(Q) At Rs 577.63 cr has Fallen at -39.0% (vs previous 4Q average)
- PAT(Q) At Rs 482.92 cr has Fallen at -31.6% (vs previous 4Q average)
- INTEREST(Q) At Rs 54.00 cr has Grown at 26.76%
3
With ROE of 26.9, it has a Attractive valuation with a 6.2 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 10.26%, its profits have risen by 177.5% ; the PEG ratio of the company is 0.1
4
High Institutional Holdings at 39.54%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
6
Consistent Returns over the last 3 years
- Along with generating 10.26% returns in the last 1 year, the stock has outperformed BSE500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Glenmark Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Glenmark Pharma for you?
Medium Risk, High Return
Absolute
Risk Adjusted
Volatility
Glenmark Pharma
10.84%
0.38
27.18%
Sensex
-2.63%
-0.20
13.57%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
8.93%
EBIT Growth (5y)
19.21%
EBIT to Interest (avg)
8.05
Debt to EBITDA (avg)
1.37
Net Debt to Equity (avg)
-0.06
Sales to Capital Employed (avg)
1.12
Tax Ratio
29.01%
Dividend Payout Ratio
6.74%
Pledged Shares
0
Institutional Holding
39.54%
ROCE (avg)
19.22%
ROE (avg)
12.43%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
21
Industry P/E
37
Price to Book Value
6.17
EV to EBIT
15.38
EV to EBITDA
13.40
EV to Capital Employed
6.48
EV to Sales
3.62
PEG Ratio
0.12
Dividend Yield
0.22%
ROCE (Latest)
40.27%
ROE (Latest)
26.86%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
PAT(Latest six months)
At Rs 1,074.48 cr has Grown at 158.76%
ROCE(HY)
Highest at 40.16%
DEBT-EQUITY RATIO(HY)
Lowest at 0.06 times
-10What is not working for the Company
PBT LESS OI(Q)
At Rs 577.63 cr has Fallen at -39.0% (vs previous 4Q average
PAT(Q)
At Rs 482.92 cr has Fallen at -31.6% (vs previous 4Q average
INTEREST(Q)
At Rs 54.00 cr has Grown at 26.76%
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.37 times
NET SALES(Q)
At Rs 4,018.48 cr has Fallen at -5.4% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is working for Glenmark Pharma
Debt-Equity Ratio - Half Yearly
Lowest at 0.06 times
in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Here's what is not working for Glenmark Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 577.63 cr has Fallen at -39.0% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 947.56 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 482.92 cr has Fallen at -31.6% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 706.01 CrMOJO Watch
Near term PAT trend is very negative
PAT (Rs Cr)
Interest - Quarterly
At Rs 54.00 cr has Grown at 26.76%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Net Sales - Quarterly
At Rs 4,018.48 cr has Fallen at -5.4% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 4,245.63 CrMOJO Watch
Near term sales trend is negative
Net Sales (Rs Cr)
Debtors Turnover Ratio- Half Yearly
Lowest at 3.37 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
